Positive takes of today's PR - India is still i
Post# of 22453
(Total Views: 692)
Posted On: 08/25/2021 10:35:40 AM
Positive takes of today's PR
- India is still in place
- in talks with a partner to develop
- a new 3rd generation proprietary perovskite quantum dot solar cell technology developed by Solterra/QMC
- we have now developed a point of care test platform (POCT)
- We are currently developing 1) LFTs (lateral flow test kits) for TBI (traumatic brain injury, aka concussions), 2) a multiplex test that detects Covid-19, Flu and RSV (Respiratory Syncytial Virus), and 3) a vaccine validator to thwart counterfeit vaccines and validate vaccine efficac
- the Company has signed a term sheet with a Canada-based biotech company that has identified and has a patent-pending on several biomarker candidates that will be used to develop the TBI POCT.
- the POCT market technology is intended to part of our immediate commercialization focus.
- We are in the process of negotiating the final terms that include the payment milestones required for QMC to design, develop, shepherd the FDA approval process, and produce the test kits.
- I can assure you that we intend to work tirelessly to restore the Company’s reporting and trading status.
Negative takes:
- increasing authorized shares (nut necessary to relist)
- no mention of using those share for pasaca buy out
-shutting down QMC Healthid (what of it's part of the Innova ecosystem)
- QMC Verify (previously QMC Ledger we have made the decision to retain this technology but to defer its further development and commercialization until the company has achieved a sustainable revenue model or strategic funding to support this technology.
- If adequate working capital is not available, we may be forced to curtail operations, which would cause you to lose your entire investment.
- India is still in place
- in talks with a partner to develop
- a new 3rd generation proprietary perovskite quantum dot solar cell technology developed by Solterra/QMC
- we have now developed a point of care test platform (POCT)
- We are currently developing 1) LFTs (lateral flow test kits) for TBI (traumatic brain injury, aka concussions), 2) a multiplex test that detects Covid-19, Flu and RSV (Respiratory Syncytial Virus), and 3) a vaccine validator to thwart counterfeit vaccines and validate vaccine efficac
- the Company has signed a term sheet with a Canada-based biotech company that has identified and has a patent-pending on several biomarker candidates that will be used to develop the TBI POCT.
- the POCT market technology is intended to part of our immediate commercialization focus.
- We are in the process of negotiating the final terms that include the payment milestones required for QMC to design, develop, shepherd the FDA approval process, and produce the test kits.
- I can assure you that we intend to work tirelessly to restore the Company’s reporting and trading status.
Negative takes:
- increasing authorized shares (nut necessary to relist)
- no mention of using those share for pasaca buy out
-shutting down QMC Healthid (what of it's part of the Innova ecosystem)
- QMC Verify (previously QMC Ledger we have made the decision to retain this technology but to defer its further development and commercialization until the company has achieved a sustainable revenue model or strategic funding to support this technology.
- If adequate working capital is not available, we may be forced to curtail operations, which would cause you to lose your entire investment.
(1)
(0)Quantum Materials Corp. (QTMM) Stock Research Links
Scroll down for more posts ▼